P3.2 Developing Country Vaccine Manufacturers - Access to Immunization | Lakshminarayana Neti | 2018 | Presentation | English |
*Meeting report: Global vaccine and immunization research forum, 2018 | Angela Hwang, B. Fenton Hall, Martin Friede, Peter Dull | 2019 | Journal article | English |
Agenda - GVIRF 2018 | GVIRF Secretariat | 2018 | Presentation | English |
Introduction to GVIRF | B. Fenton Hall | 2018 | Presentation | English |
KN1 Beyond effectiveness: research on vaccines seen as a continuum | Alejandro Cravioto | 2018 | Presentation | English |
KN2 National and regional capacity for biotechnology research; Indian experience | Maharaj Kishan Bhan | 2018 | Presentation | English |
P1 Progress Towards and Commonalities in Vaccine Development Against HIV, TB, and Malaria | Mary Marovich | 2018 | Report | English |
P1.1 Advanced Clinical Development of HIV Vaccines | K. T. Mngadi | 2018 | Presentation | English |
P1.2 Commonalities across vaccine development efforts | Punnee Pitisuttithum | 2018 | Presentation | English |
P1.3 Progress towards vaccines against TB | Gerald Voss | 2018 | Presentation | English |
P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine development | Fred Binka | 2018 | Presentation | English |
P1.5 Gaps in Malaria Vaccines | J. Kevin Baird | 2018 | Presentation | English |
P2 Innovating for Equity | Narendra Arora | 2018 | Report | English |
P2.1 Intensified Mission Indradhanush: Addressing Equity in Immunization | Pradeep Haldar | 2018 | Presentation | English |
P2.2 Use of Multiple Measures for Immunization Management in Migratory Population | Lin Luan | 2018 | Presentation | English |
P2.4 Social Media Initiative in Ukraine: Analysis of Conversations on Polio, Vaccination and Routine Immunization | Anna Postovoitova | 2018 | Presentation | English |
P2.5 Universal Health Coverage: a people-centred approach | Birgitte Giersing | 2018 | Presentation | English |
P2.6 Strengthening Vaccination Programs among the Urban Poor: Closing the Equity Gap | Folake Olayinka | 2018 | Presentation | English |
P3 Growing Developing Country Vaccine Manufacture | A. A. Adeyemo | 2018 | Report | English |
P3.1 Vaccine Production in Developing Countries: an Economic Evaluation | Syarifah Liza Munira | 2018 | Presentation | English |
P3.3 Vaccine Manufacturing in Developing Countries: Perspectives on Approaches to Take, and Factors to Consider, towards Sustainable Manufacturing Capacity | Martin Nicholson | 2018 | Presentation | English |
P3.4 Addressing Patent Barriers to Vaccine Development & Access | Kate Elder | 2018 | Presentation | English |
P4 Regulatory Capacity, Challenges, and Convergences | Norman W. Baylor | 2018 | Report | English |
P4.1 Alternative Regulatory Pathways: Opportunities and Challenges | Norman W. Baylor | 2018 | Presentation | English |
P4.2 Benefits and Challenges: How regulators can reduce time and efforts in the case of public health emergencies? | Yeowon Sohn | 2018 | Presentation | English |
P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from Thailand | Akanid Wapeewuttikorn | 2018 | Presentation | English |
P5 Evidence for Decision Making | David Kaslow, Robert Breiman | | Report | English |
P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseases | David Kaslow | 2018 | Presentation | English |
P5.2 Evidence for Decision Making | Yot Teerawattananon | 2018 | Presentation | English |
P6 Polio Endgame: Needs and Opportunities | Roland Sutter | | Report | English |
P6.1 Intro Polio Endgame: Needs and Opportunities | Roland Sutter | 2018 | Presentation | English |
P6.2 Global tOPV withdrawal: "The Switch" experience | Alejandro Ramirez Gonzalez | 2018 | Presentation | English |
P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2? | Ondrej Mach | 2018 | Presentation | English |
P6.4 Polio Vaccines - R&D Updates | Peter Dull | 2018 | Presentation | English |
P6.5 Research for polio policy making: Lessons learned | Roland Sutter | 2018 | Presentation | English |
P7 Discussion with Thought Leaders | Peter Dull | 2018 | Report | English |
W1 Emerging Vaccine Strategies & Technologies | Paula Bryant | 2018 | Report | English |
W1.1 MIMIC: an in vitro model of human immunity | Don Drake | 2018 | Presentation | English |
W1.2 New Vaccine Strategies using cytomegalovirus | Klaus Früh | 2018 | Presentation | English |
W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) Vaccines | Johan Neyts, Kai Dallmeier | 2018 | Presentation | English |
W2 R&D Update: Enteric Vaccines | Gagandeep Kang, Jean-Pierre Amorij | 2018 | Report | English |
W2.1 An update on rotavirus vaccines | Gagandeep Kang | 2018 | Presentation | English |
W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccines | Cal MacLennan | 2018 | Presentation | English |
W2.3 Controlled Human Infection Models and Enteric Vaccine Development | Beth Kirkpatrick | 2018 | Presentation | English |
W3 Pneumococcal Vaccines: Lessons Learned and the Road Ahead | Hani Kim | 2018 | Report | English |
W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and Impact | Katherine L. O'Brien | 2018 | Presentation | English |
W3.2 Rollout of Pneumococcal Conjugate Vaccine in India | Narendra K Arora, Pradeep Haldar | 2018 | Presentation | English |
W3.3 The Future of Pneumococcal Conjugate Vaccines | Keith Klugman | 2018 | Presentation | English |
W4 Immunological Principles of Vaccines and Vaccination | Annie Mo, Bernhards Ogutu | 2018 | Report | English |
W4.1 New Approaches to Understanding Human Immunity | Annie Mo | 2018 | Presentation | English |